Galectin-3-independent prognosis in heart failure

Clinical Research in Cardiology

Volumn 100, Issue 2, 2011, Pages 183-

  Carrasco Sánchez, Francisco Javier ^a  

^a Internal Medicine Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; GALECTIN 3;

DISEASE ASSOCIATION; HEART FAILURE; HUMAN; LETTER; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; ENDOMYOCARDIAL FIBROSIS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 79953887825     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0245-4     Document Type: Letter

References (3)

1. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 99:323-328
2. Cook NR (2008) Statistical evaluation of prognostic versus diagnostic models: Beyond the ROC curve. Clin Chem 54:17-23 (Pubitemid 351182592)
3. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172 (Pubitemid 351193639)